NCT05038618View on ClinicalTrials.gov

A Study o Evaluate the Safety, Tolerability, and Immunogenicity of MVC-COV1901, CT-COV-21 Sub-study

PHASE2CompletedINTERVENTIONAL

Enrollment

399

Participants

Timeline

Start Date

August 2, 2021

Primary Completion Date

October 14, 2021

Study Completion Date

March 11, 2022

Conditions

Covid19 Vaccine

Interventions

BIOLOGICAL

MVC-COV1901(S protein with adjuvant)

Approximately 400 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region

Trial Locations (1)

Unknown

Chang-Guang Memorial Hospital Lin-Kou, Taoyuan District